Desq Long
Sign in

Company

Spyre Therapeutics, Inc.

SYRE · CIK 0001636282

SEC FORM 4
$108,750.00

Spyre Therapeutics, Inc. (SYRE)

Acquisition (code M) of 7,500 shares at $14.50 per share.

Reporting Person Burrows Scott L · Officer Title Chief Financial Officer · Transaction Code M

Traded Oct 1, 2026 · Disclosed Oct 2, 2026

Source: SEC Form 4 · 0001636282-26-000117 · filed 2026-10-02 · View filing →

SEC FORM 4
$53,442.00

Spyre Therapeutics, Inc. (SYRE)

Sale of 600 shares at $89.07 per share.

Reporting Person Burrows Scott L · Officer Title Chief Financial Officer · Transaction Code S

Traded Oct 1, 2026 · Disclosed Oct 2, 2026

Source: SEC Form 4 · 0001636282-26-000117 · filed 2026-10-02 · View filing →

SEC FORM 4
$135,405.00

Spyre Therapeutics, Inc. (SYRE)

Sale of 1,500 shares at $90.27 per share.

Reporting Person Burrows Scott L · Officer Title Chief Financial Officer · Transaction Code S

Traded Oct 1, 2026 · Disclosed Oct 2, 2026

Source: SEC Form 4 · 0001636282-26-000117 · filed 2026-10-02 · View filing →

SEC FORM 4
$193,032.00

Spyre Therapeutics, Inc. (SYRE)

Sale of 2,100 shares at $91.92 per share.

Reporting Person Burrows Scott L · Officer Title Chief Financial Officer · Transaction Code S

Traded Oct 1, 2026 · Disclosed Oct 2, 2026

Source: SEC Form 4 · 0001636282-26-000117 · filed 2026-10-02 · View filing →

SEC FORM 4
$285,449.45

Spyre Therapeutics, Inc. (SYRE)

Sale of 3,071 shares at $92.95 per share.

Reporting Person Burrows Scott L · Officer Title Chief Financial Officer · Transaction Code S

Traded Oct 1, 2026 · Disclosed Oct 2, 2026

Source: SEC Form 4 · 0001636282-26-000117 · filed 2026-10-02 · View filing →

SEC FORM 4
$21,427.53

Spyre Therapeutics, Inc. (SYRE)

Sale of 229 shares at $93.57 per share.

Reporting Person Burrows Scott L · Officer Title Chief Financial Officer · Transaction Code S

Traded Oct 1, 2026 · Disclosed Oct 2, 2026

Source: SEC Form 4 · 0001636282-26-000117 · filed 2026-10-02 · View filing →

SEC FORM 4
$53,484.00

Spyre Therapeutics, Inc. (SYRE)

Sale of 600 shares at $89.14 per share.

Reporting Person Turtle Cameron · Officer Title Chief Executive Officer · Transaction Code S

Traded Oct 1, 2026 · Disclosed Oct 2, 2026

Source: SEC Form 4 · 0001636282-26-000118 · filed 2026-10-02 · View filing →

SEC FORM 4
$241,738.30

Spyre Therapeutics, Inc. (SYRE)

Sale of 2,683 shares at $90.10 per share.

Reporting Person Turtle Cameron · Officer Title Chief Executive Officer · Transaction Code S

Traded Oct 1, 2026 · Disclosed Oct 2, 2026

Source: SEC Form 4 · 0001636282-26-000118 · filed 2026-10-02 · View filing →

SEC FORM 4
$241,350.62

Spyre Therapeutics, Inc. (SYRE)

Sale of 2,638 shares at $91.49 per share.

Reporting Person Turtle Cameron · Officer Title Chief Executive Officer · Transaction Code S

Traded Oct 1, 2026 · Disclosed Oct 2, 2026

Source: SEC Form 4 · 0001636282-26-000118 · filed 2026-10-02 · View filing →

SEC FORM 4
$368,224.59

Spyre Therapeutics, Inc. (SYRE)

Sale of 3,989 shares at $92.31 per share.

Reporting Person Turtle Cameron · Officer Title Chief Executive Officer · Transaction Code S

Traded Oct 1, 2026 · Disclosed Oct 2, 2026

Source: SEC Form 4 · 0001636282-26-000118 · filed 2026-10-02 · View filing →

SEC FORM 4
$465,916.30

Spyre Therapeutics, Inc. (SYRE)

Sale of 4,990 shares at $93.37 per share.

Reporting Person Turtle Cameron · Officer Title Chief Executive Officer · Transaction Code S

Traded Oct 1, 2026 · Disclosed Oct 2, 2026

Source: SEC Form 4 · 0001636282-26-000118 · filed 2026-10-02 · View filing →

SEC FORM 4
$9,391.00

Spyre Therapeutics, Inc. (SYRE)

Sale of 100 shares at $93.91 per share.

Reporting Person Turtle Cameron · Officer Title Chief Executive Officer · Transaction Code S

Traded Oct 1, 2026 · Disclosed Oct 2, 2026

Source: SEC Form 4 · 0001636282-26-000118 · filed 2026-10-02 · View filing →

SEC FORM 4
$419,528.50

Spyre Therapeutics, Inc. (SYRE)

Acquisition (code M) of 28,933 shares at $14.50 per share.

Reporting Person King-Jones Heidy · Officer Title See Remarks · Transaction Code M

Traded Oct 1, 2026 · Disclosed Oct 2, 2026

Source: SEC Form 4 · 0001636282-26-000119 · filed 2026-10-02 · View filing →

SEC FORM 4
$35,696.00

Spyre Therapeutics, Inc. (SYRE)

Sale of 400 shares at $89.24 per share.

Reporting Person King-Jones Heidy · Officer Title See Remarks · Transaction Code S

Traded Oct 1, 2026 · Disclosed Oct 2, 2026

Source: SEC Form 4 · 0001636282-26-000119 · filed 2026-10-02 · View filing →

SEC FORM 4
$1,500,261.75

Spyre Therapeutics, Inc. (SYRE)

Sale of 16,605 shares at $90.35 per share.

Reporting Person King-Jones Heidy · Officer Title See Remarks · Transaction Code S

Traded Oct 1, 2026 · Disclosed Oct 2, 2026

Source: SEC Form 4 · 0001636282-26-000119 · filed 2026-10-02 · View filing →

SEC FORM 4
$660,277.80

Spyre Therapeutics, Inc. (SYRE)

Sale of 7,228 shares at $91.35 per share.

Reporting Person King-Jones Heidy · Officer Title See Remarks · Transaction Code S

Traded Oct 1, 2026 · Disclosed Oct 2, 2026

Source: SEC Form 4 · 0001636282-26-000119 · filed 2026-10-02 · View filing →

SEC FORM 4
$194,670.00

Spyre Therapeutics, Inc. (SYRE)

Sale of 2,100 shares at $92.70 per share.

Reporting Person King-Jones Heidy · Officer Title See Remarks · Transaction Code S

Traded Oct 1, 2026 · Disclosed Oct 2, 2026

Source: SEC Form 4 · 0001636282-26-000119 · filed 2026-10-02 · View filing →

SEC FORM 4
$242,996.00

Spyre Therapeutics, Inc. (SYRE)

Sale of 2,600 shares at $93.46 per share.

Reporting Person King-Jones Heidy · Officer Title See Remarks · Transaction Code S

Traded Oct 1, 2026 · Disclosed Oct 2, 2026

Source: SEC Form 4 · 0001636282-26-000119 · filed 2026-10-02 · View filing →

SEC FORM 4
$253,750.00

Spyre Therapeutics, Inc. (SYRE)

Acquisition (code M) of 17,500 shares at $14.50 per share.

Reporting Person Burrows Scott L · Officer Title Chief Financial Officer · Transaction Code M

Traded Sep 30, 2026 · Disclosed Oct 2, 2026

Source: SEC Form 4 · 0001636282-26-000117 · filed 2026-10-02 · View filing →

SEC FORM 4
$1,573,075.00

Spyre Therapeutics, Inc. (SYRE)

Sale of 17,500 shares at $89.89 per share.

Reporting Person Burrows Scott L · Officer Title Chief Financial Officer · Transaction Code S

Traded Sep 30, 2026 · Disclosed Oct 2, 2026

Source: SEC Form 4 · 0001636282-26-000117 · filed 2026-10-02 · View filing →

SEC FORM 4
$1,629,029.20

Spyre Therapeutics, Inc. (SYRE)

Sale of 18,232 shares at $89.35 per share.

Reporting Person Burrows Scott L · Officer Title Chief Financial Officer · Transaction Code S

Traded Sep 2, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001636282-26-000109 · filed 2026-09-03 · View filing →

SEC FORM 4
$5,800.00

Spyre Therapeutics, Inc. (SYRE)

Acquisition (code M) of 400 shares at $14.50 per share.

Reporting Person King-Jones Heidy · Officer Title See Remarks · Transaction Code M

Traded Sep 2, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001636282-26-000111 · filed 2026-09-03 · View filing →

SEC FORM 4
$36,000.00

Spyre Therapeutics, Inc. (SYRE)

Sale of 400 shares at $90 per share.

Reporting Person King-Jones Heidy · Officer Title See Remarks · Transaction Code S

Traded Sep 2, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001636282-26-000111 · filed 2026-09-03 · View filing →

SEC FORM 4
$215,900.00

Spyre Therapeutics, Inc. (SYRE)

Sale of 2,500 shares at $86.36 per share.

Reporting Person Turtle Cameron · Officer Title Chief Executive Officer · Transaction Code S

Traded Sep 1, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001636282-26-000107 · filed 2026-09-03 · View filing →

SEC FORM 4
$732,060.00

Spyre Therapeutics, Inc. (SYRE)

Sale of 8,400 shares at $87.15 per share.

Reporting Person Turtle Cameron · Officer Title Chief Executive Officer · Transaction Code S

Traded Sep 1, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001636282-26-000107 · filed 2026-09-03 · View filing →

SEC FORM 4
$325,822.00

Spyre Therapeutics, Inc. (SYRE)

Sale of 3,700 shares at $88.06 per share.

Reporting Person Turtle Cameron · Officer Title Chief Executive Officer · Transaction Code S

Traded Sep 1, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001636282-26-000107 · filed 2026-09-03 · View filing →

SEC FORM 4
$35,628.00

Spyre Therapeutics, Inc. (SYRE)

Sale of 400 shares at $89.07 per share.

Reporting Person Turtle Cameron · Officer Title Chief Executive Officer · Transaction Code S

Traded Sep 1, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001636282-26-000107 · filed 2026-09-03 · View filing →

SEC FORM 4
$108,750.00

Spyre Therapeutics, Inc. (SYRE)

Acquisition (code M) of 7,500 shares at $14.50 per share.

Reporting Person Burrows Scott L · Officer Title Chief Financial Officer · Transaction Code M

Traded Sep 1, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001636282-26-000109 · filed 2026-09-03 · View filing →

SEC FORM 4
$77,625.00

Spyre Therapeutics, Inc. (SYRE)

Sale of 900 shares at $86.25 per share.

Reporting Person Burrows Scott L · Officer Title Chief Financial Officer · Transaction Code S

Traded Sep 1, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001636282-26-000109 · filed 2026-09-03 · View filing →

SEC FORM 4
$381,890.24

Spyre Therapeutics, Inc. (SYRE)

Sale of 4,384 shares at $87.11 per share.

Reporting Person Burrows Scott L · Officer Title Chief Financial Officer · Transaction Code S

Traded Sep 1, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001636282-26-000109 · filed 2026-09-03 · View filing →

SEC FORM 4
$177,468.48

Spyre Therapeutics, Inc. (SYRE)

Sale of 2,016 shares at $88.03 per share.

Reporting Person Burrows Scott L · Officer Title Chief Financial Officer · Transaction Code S

Traded Sep 1, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001636282-26-000109 · filed 2026-09-03 · View filing →

SEC FORM 4
$17,808.00

Spyre Therapeutics, Inc. (SYRE)

Sale of 200 shares at $89.04 per share.

Reporting Person Burrows Scott L · Officer Title Chief Financial Officer · Transaction Code S

Traded Sep 1, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001636282-26-000109 · filed 2026-09-03 · View filing →

SEC FORM 4
$405,985.50

Spyre Therapeutics, Inc. (SYRE)

Acquisition (code M) of 27,999 shares at $14.50 per share.

Reporting Person King-Jones Heidy · Officer Title See Remarks · Transaction Code M

Traded Sep 1, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001636282-26-000111 · filed 2026-09-03 · View filing →

SEC FORM 4
$418,608.00

Spyre Therapeutics, Inc. (SYRE)

Sale of 4,845 shares at $86.40 per share.

Reporting Person King-Jones Heidy · Officer Title See Remarks · Transaction Code S

Traded Sep 1, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001636282-26-000111 · filed 2026-09-03 · View filing →

SEC FORM 4
$1,442,985.60

Spyre Therapeutics, Inc. (SYRE)

Sale of 16,548 shares at $87.20 per share.

Reporting Person King-Jones Heidy · Officer Title See Remarks · Transaction Code S

Traded Sep 1, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001636282-26-000111 · filed 2026-09-03 · View filing →

SEC FORM 4
$547,183.02

Spyre Therapeutics, Inc. (SYRE)

Sale of 6,206 shares at $88.17 per share.

Reporting Person King-Jones Heidy · Officer Title See Remarks · Transaction Code S

Traded Sep 1, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001636282-26-000111 · filed 2026-09-03 · View filing →

SEC FORM 4
$35,752.00

Spyre Therapeutics, Inc. (SYRE)

Sale of 400 shares at $89.38 per share.

Reporting Person King-Jones Heidy · Officer Title See Remarks · Transaction Code S

Traded Sep 1, 2026 · Disclosed Sep 3, 2026

Source: SEC Form 4 · 0001636282-26-000111 · filed 2026-09-03 · View filing →